Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 896 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo oral pills Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Seaweed-derived Rhamnan Sulfate and Vascular Function

NCT05651230
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Rhamnan sulfate
Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
35 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

NCT03679598
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD
Interventions
Alvelestat (MPH966), Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

NCT00775463
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
treprostinil diethanolamine, placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Buproprion for Binge Drinking

NCT03169244
View directory record Official record
Conditions
Alcohol Abuse
Interventions
Bupropion, Placebo Oral Tablet
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 44 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Results available

Oral Caffeine Use for Pain Management in AIS Patients After Spinal Fusion

NCT04950660
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Caffeine Tablet, Placebo
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Minocycline Study in Pancreatic Cancer Patients

NCT01693523
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Minocycline, Placebo, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 9, 2026, 9:58 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

NCT04971720
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases, Hypertension, Nocturnal Blood Pressure, Natriuretic Peptides, Renin-Angiotensin-Aldosterone System
Interventions
Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet, Valsartan 80 mg Oral Tablet
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Results available

Zoster Eye Disease Study

NCT03134196
View directory record Official record
Conditions
Herpes Zoster Ophthalmicus
Interventions
Masked Placebo, Masked Oral Valacyclovir
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
71
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects

NCT03310359
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Astaxanthin, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

NCT02301897
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Telapristone Acetate, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 9, 2026, 9:58 AM EDT
Not yet recruiting Phase 4 Interventional

Discontinuation of Low-Dose Levothyroxine in Older Adults With Subclinical Hypothyroidism

NCT07787585
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine Pill, Placebo
Drug
Lead sponsor
Spyridoula Maraka
Other
Eligibility
65 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
3
States / cities
Little Rock, Arkansas • Gainesville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanistic Characterization of Uterine Pain

NCT04145518
View directory record Official record
Conditions
Dysmenorrhea (Disorder), Dysmenorrhea Primary, Dysmenorrhea Secondary, Endometrial Diseases, Leiomyoma, Fibroid Uterus
Interventions
Naproxen Sodium, Placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response

NCT02372110
View directory record Official record
Conditions
Anxiety
Interventions
HPA, ANS stimulation, Placebo
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial of Rosiglitazone for Ulcerative Colitis

NCT00065065
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
James Lewis
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
13
States / cities
Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of Continuous Oral Contraceptives and Doxycycline

NCT00480532
View directory record Official record
Conditions
Contraceptives, Oral
Interventions
Lybrel, Doxycycline, Oracea, Placebo, Doxycycline 100bid x5 days at the time of bleeding, Subantimicrobial doxycycline daily, placebo daily
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
2
States / cities
Honolulu, Hawaii • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glyburide Healthy Volunteer Study

NCT01716338
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glyburide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Lower Limb Function After Spinal Cord Injury

NCT02635893
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
D-Cycloserine, Placebo, Training, Stimulation, Placebo Stimulation
Drug · Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 85 Years
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 3 Interventional

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients

NCT00561093
View directory record Official record
Conditions
Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress, Chronic Kidney Disease (CKD) Hemodialysis
Interventions
pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa), Placebo pill imitating pentoxiphylline, Placebo to imitate Nepro, Placebo to imitate anti-inflammatory module (similar to Oxepa)
Drug · Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Irvine, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)

NCT01988571
View directory record Official record
Conditions
Breast Cancer, Lymphoma
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 100 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
51
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 9, 2026, 9:58 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Lorazepam Effects on Neuroimaging Measures

NCT04671836
View directory record Official record
Conditions
Lorazepam, Neuroimaging
Interventions
Lorazepam 1Mg Tablet, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

Induction of Clinical Response Using Rifaximin in Crohn's Disease

NCT00603616
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo Comparator, Rifaximin
Drug
Lead sponsor
Scott Lee
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 9, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Results available

Tolvaptan in Hyponatremic Cancer Patients

NCT01199198
View directory record Official record
Conditions
Advanced Cancers
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 9, 2026, 9:58 AM EDT
Withdrawn Phase 2 Interventional

Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia

NCT00538564
View directory record Official record
Conditions
Sickle Cell Anemia, Priapism
Interventions
tadalafil, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Oct 9, 2026, 9:58 AM EDT